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Rotarix in Japan: Expectations and Concerns
Osamu Nakagomi · Toyoko Nakagomi
ABSTRACT
A live-attenuated, orally-administered, 
monovalent, human rotavirus vaccine, Rotarix® 
(GlaxoSmithKline Biologicals, Rixensart, 
Belgium), was licensed and launched in 2011 as 
the first rotavirus vaccine in Japan. The rotavirus 
causes a substantial disease burden with an 
estimated 790,000 outpatient visits, 27,000-
78,000 hospitalizations, and approximately 
10 deaths each year in Japan. Since a recent 
clinical trial showed that Rotarix was as 
efficacious in Japan as in other industrialized 
countries, it is expected that the annual number 
of rotavirus hospitalizations will be reduced 
to between 1000-3000, and that outpatient 
visits will be reduced to 200,000. The universal 
rotavirus immunization program with Rotarix 
was calculated to be at the threshold of being 
cost-effective, even from the healthcare 
perspective, and it was highly cost-effective 
from the societal perspective, assuming that 
Rotarix is co-administered with other childhood 
vaccines. While Rotarix contains only a single 
G1P[8] human rotavirus, the postlicensure 
studies in Brazil showed that Rotarix provided 
a 75%-85% protective efficacy against severe 
dehydrating diarrhea or hospitalizations due 
to fully-heterotypic G2P[4] strains. While 
postlicensure studies detected a small and 
finite risk of intussusception associated with 
the administration of Rotarix, the authors 
conclude that Rotarix is safe to administer to 
infants between 6-12 weeks of age for the first 
dose and by 24 weeks of age for the second 
dose. However, the authors strongly discourage 
the delayed administration of the first dose 
between 13-20 weeks of age, which is allowed 
without any warning. Given the high incidence 
of naturally-occurring intussusception in Japan 
(185 cases per 100,000 children/year among 
children less than 1 year of age), this should 
prevent pediatricians and parents from having 
ill-perceptions of Rotarix being associated with 
an increased number of temporally-associated 
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intussusception, and fully appreciate the benefit 
of the rotavirus vaccine. 
Keywords: diarrhea; heterotypic immunity; 
immunization; intussusception; Japan; Rotarix; 
rotavirus 
INTRODUCTION
Acute diarrhea is the leading cause of childhood 
morbidity and mortality worldwide, accounting 
for approximately 15% of deaths occurring in 
children less than 5 years of age.1 Rotavirus has 
been recognized as the single most important 
etiological agent of severe diarrhea2 causing an 
estimated 453,000 deaths annually.3 Thus, after 
reviewing the recent efficacy data generated by 
studies on Rotarix® (GlaxoSmithKline Biologicals, 
Rixensart, Belgium) in African countries, the 
Strategic Advisory Group of Experts of the 
World Health Organization (WHO) in 2009 
recommended incorporation of rotavirus 
vaccines into the national immunization 
programs of all countries, with an emphasis in 
those regions where mortality rates in children 
less than 5 years of age are ≥10%.4-6 Two major 
rotavirus vaccines that were prequalified by the 
WHO are the monovalent, human rotavirus-
based vaccine, Rotarix,7 and the pentavalent, 
bovine-human re-assortant vaccine, RotaTeq® 
(Merck & Co, Inc., NJ, USA).8 These rotavirus 
vaccines are licensed in more than 120 countries, 
but it was not until 2011 that the Ministry of 
Health, Labor, and Welfare in Japan approved the 
rotavirus vaccine (Rotarix) for use in infants to 
prevent rotavirus gastroenteritis. In this review 
the authors briefly describe two important issues 
to understand the rotavirus vaccine: the nature 
of protective immunity after natural rotavirus 
infection and the burden of rotavirus diarrhea 
in Japan. The authors then concisely summarize 
the product profile of Rotarix that is most 
relevant in practice. Finally, the authors address 
two key issues for practitioners and parents: 
the efficacy of Rotarix against fully heterotypic 
strains and the safety of Rotarix with respect to 
intussusception. 
ROTAVIRUS AND ITS SEROTYPES
Rotavirus, taxonomically a species (Rotavirus 
A) within genus Rotavirus, family Reoviridae, is 
a nonenveloped RNA virus with icosahedral 
symmetry.9 The outer surface of the virion consists 
of viral spikes (made up of the VP4 trimers) and 
the outercapsid proteins (made up of the VP7 
trimers).9 Both VP4 and VP7 independently 
serve as a neutralization antigen, and define 
the protease-sensitive protein (P) type and the 
glycoprotein (G) type, respectively.2,9 While 
serotype should, by definition, be determined by 
serologic assays, molecular assays have replaced 
serologic assays in the determination of G and P
types of a rotavirus in clinical specimens; hence, 
referred to as the genotype.9 While there is an 
exact match between G serotype and G genotype, 
different numbering systems were adopted 
to designate P serotype and P genotype, with 
P genotype being designated within squared 
brackets. Thus, the P serotype of RIX4414, the 
vaccine strain in Rotarix, is P1A, whereas its 
P genotype is P[8]. There are 27 G genotypes and 
35 P genotypes described to date,10 but the G and P 
type combinations detected in human rotaviruses 
are mostly limited to G1P[8], G2P[4], G3P[8], 
G4P[8], and G9P[8].11,12 However, previously rare 
G12 strains appear to have emerged across the 
globe13-15 and G8 strains, with either P[6] or P[4], 
account for a significant proportion of human 
rotavirus strains in Africa.16,17 Such genetic 
diversity appears to be generated by frequent 
reassortment of the genome segments and 
interspecies transmission of rotaviruses between 
humans and animals.18-21
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PROTECTIVE IMMUNITY AFTER 
NATURAL INFECTION AND 
THE GUIDING PRINCIPLE OF 
ROTAVIRUS VACCINES
Complete protection against moderate-to-severe 
rotavirus-associated diarrhea, but not against 
mild diarrhea or infection itself, is obtained after 
asymptomatic infection in the neonatal period22
or after two infections with rotavirus, regardless 
of whether the infections are symptomatic or 
asymptomatic.23 In a cohort study in Mexico,23 
the adjusted efficacy in protecting against 
subsequent rotavirus infection was 38% after 
one infection, 60% after two infections, and 66% 
after three infections. In contrast, the efficacy 
against rotavirus-associated diarrhea of any 
severity was 77% after one infection, 83% after 
two infections, and 92% after three infections. 
Against moderate-to-severe rotavirus-associated 
diarrhea, protection is greater with 87% after one 
infection and 100% after two or three infections. 
In the same study, repeated infections with the 
same G type were less likely to occur, suggesting 
the presence of homotypic immunity. It is 
generally believed that, while infection with one 
serotype provides serotype-specific (homotypic) 
protection, repeated infections tend to provide 
broader protection that exerts over different 
serotypes; ie, heterotypic protection.24 Thus, 
it is clear from the natural history of rotavirus 
infection that the aim of the rotavirus vaccine 
should be to prevent severe, dehydrating 
diarrhea and deaths due to rotavirus infection in 
the first 3 years of life when rotavirus-associated 
diarrhea is most severe, rather than to prevent 
mild diarrhea or infection.25 However, this 
guiding principle was challenged by a recent 
study in India that showed a much lower 
protection effect of natural rotavirus infection 
against subsequent diseases in a setting with 
high viral load and diversity.26
THE BURDEN OF ROTAVIRUS 
DIARRHEA IN JAPAN
Given that the aim of the rotavirus vaccine is 
to reduce the burden of rotavirus-associated 
diarrhea in the society, the key information is the 
annual number of cases of rotavirus-associated 
diarrhea and the associated cost. The cost needs 
to be viewed from both the healthcare and the 
societal perspectives. With regard to the annual 
number of cases of rotavirus-associated diarrhea, 
the most important is the number of rotavirus 
hospitalization at a national level and whether the 
estimated reduction of the disease burden will be 
cost-effective. The major difference between the 
cost calculated from the healthcare perspective 
and that calculated from the societal perspective 
is that the latter includes the productivity loss of 
care-givers of sick children. This productivity loss 
accounts for the vast majority of the indirect cost 
associated with rotavirus-associated diarrhea.27,28
The birth cohort in Japan is approximately 
1 million and the information required is the 
number of children who will be hospitalized 
due to rotavirus-associated diarrhea when the 
cohort is followed for 5 years. Only a few studies 
are available in Japan, and it was estimated 
that there were 790,000 outpatient visits,29
27,000-78,000 hospitalizations,30-32 and 
approximately 10 deaths due to rotavirus 
gastroenteritis in the entire country. The 
variability in the estimate of the annual 
number of rotavirus hospitalizations was due 
to the variability in the incidence of rotavirus 
hospitalizations in different locations and dates 
in Japan: 4.9 per 1000 children/year in the Mie 
prefecture between 2003-2007,30 5.3 per 1000 
children/year in the Kyoto prefecture between 
2008-2010,31 and 13 per 1000 children/year in 
the Akita prefecture between 2001-2002.32 These 
variable incidences, however, were not dissimilar 
from those reported from other industrialized 
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countries; for example, in seven European 
countries that included Belgium, France, 
Germany, Italy, Spain, Sweden, and the UK (the 
REVEAL study), the incidence ranged from a 
minimum of 2.9 per 1000 children/year in the 
UK to a maximum of 9.9 per 1000 children/year
in Belgium, with a median of 6.5 per
1000 children/year in Spain.33,34
If the rotavirus vaccine is as efficacious in 
Japan as in other industrialized countries, it is 
expected that the annual number of rotavirus 
hospitalizations could be reduced to between 
1000-3000, and that the number of the outpatient 
visits could be reduced to 200,000. To determine 
whether this reduction will be cost-effective, 
one needs to calculate the incremental cost-
effectiveness ratio (ICER) per quality-adjusted 
life year (QALY) gained. In Japan, a prevention 
measure is said to be cost-effective if its ICER per 
QALY gained is JPY 6 million. From a healthcare 
perspective, the universal rotavirus immunization 
program with Rotarix was calculated to be almost 
at the threshold of being cost-effective, assuming 
the vaccine cost of JPY 20,000 per course. From 
the societal perspective, it was highly cost-effective 
with an ICER of JPY 900,000 per QALY gained.28 
A caveat to this analysis is that the authors 
assumed co-administration of Rotarix with other 
childhood vaccines. However, co-administration is 
unpopular under the current situation in Japan (see 
later). If given independently from other vaccines, 
the productivity loss arising from the rotavirus 
immunization would become substantial, and the 
rotavirus vaccination would be less cost-effective, 
with an ICER of JPY 8.8 million per QALY gained.28
PRODUCT PROFILE OF ROTARIX
Indications
Rotarix is indicated for the prevention of 
rotavirus gastroenteritis. Its protective efficacy 
is suggested against rotavirus strains carrying 
G1P[8], G2P[4], G3P[8], G4P[8], or G9P[8].35
Product Specifications of Rotarix
Rotarix contains a live-attenuated G1P[8] 
human rotavirus strain, RIX4414, that contains 
at least 1 million median cell culture infective 
dose (CCID50) in 1.5 mL of calcium carbonate 
buffer. While a ready-to-use liquid formulation 
is a welcome addition, a 50% increase in volume 
from the formulation that requires reconstitution 
(1 mL) may present technical inconvenience to 
the oral administration of the liquid into the 
mouth of small infants of as early as 6 weeks of 
age. This larger volume of the liquid formulation 
relates to the content of sucrose (excipient) in 
the liquid formulation, which is higher than 
that used in the lyophilized vaccine that is 
reconstituted with 1 mL of calcium bicarbonate 
buffer.36
The Standard Schedule and the Upper Limits 
of Age for Administration
Rotarix is to be administered orally in a two-
dose schedule. According to the package insert,35
the first dose should be administered to infants 
beginning at 6 weeks of age and the second dose 
should be completed by 24 weeks of age, with 
an interval of at least 4 weeks between the first 
and the second dose (Figure 1). The company’s 
official promotion pamphlet clearly illustrates 
that the period for the first dose is between 
6-20 weeks, and that the period for the second 
dose is between 10-24 weeks.37
Globally, the upper-limit of age for the 
first dose is an important issue that may 
significantly affect the uptake rate of the vaccine 
and the increase in the temporally associated 
cases of intussusception. Naturally-occurring 
intussusception is rare in the first 3 months of age 
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but it increases rapidly thereafter38,39 (Figure 240).
The WHO recommends that the first dose 
should be administered at age 6-15 weeks.41 In 
Australia, the first dose of Rotarix is scheduled 
to be given to infants between 6-14 weeks 
of age (Figure 1).42 In the US, the Advisory 
Committee on Immunization Practices (ACIP) 
revised its recommendation in 2009 to extend 
the maximum age for the first dose to be 
14 weeks and 6 days,43 but it clearly stated 
that vaccination should not be initiated for 
infants after 15 weeks and 0 days (Figure 1). 
In Europe, the European Medicines Agency44 
states that both doses should preferably be 
administered before 16 weeks of age, meaning 
that the first dose is to be given to infants at 
Figure 1. The age period during which the first and the second dose of Rotarix are to be administered according to the 
package insert distributed in Japan. The first dose may start at 6 weeks of age but before 20 weeks of age, and the second dose 
may start at 10 weeks of age and end before 24 weeks of age. In Europe, the upper limit of the first dose is 12 weeks, while in 
the US and Australia it is 14 weeks. As the first dose of Rotarix is allowed to be given to infants between 13-20 weeks of age 
in Japan (the area highlighted in green), a concern arises that there will be an increased number of Rotarix recipients who 
develop intussusception by chance alone in the first week after the first dose.
Period of rst dose given in the 
large clinical trial in Latin 




e upper age limit for rst dose
in Europe
e upper age limit for rst dose in 
the US and Australia
Period during which rst dose is
allowed to be administered as per
package insert: 13-20 weeks of age
14 weeks12 weeks
4 weeks 24 weeks
20 weeks6 weeks
10 weeks
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6 weeks and no later than 12 weeks of age
(a minimum interval of 4 weeks between the 
doses being taken into account; Figure 1). 
The expert group of the European Society for 
Paediatric Diseases and the European Society for 
Paediatric Gastroenterology, Hepatology, and 
Nutrition (ESPID/ESPGHAN) also recommended 
that the first dose of rotavirus vaccine should be 
given between 6-12 weeks of age, and did not 
recommend catch-up vaccination with the first 
dose in infants older than 3 months of age.45
Failed Administration (Regurgitation)
The Rotarix package insert states that a single 
replacement dose may be given at the same 
vaccination visit in the event that the infant 
spits out or regurgitates most of the vaccine 
dose.35 The ACIP does not recommend re-dosing 
after regurgitation of any amount on the basis 
of the absence of data on the benefits or risks 
with re-dosing.43 From a practical perspective, 
who should pay the cost of re-dosing may also 
be an issue.
Concomitant Vaccine Administration
In countries where Rotarix is given as part of 
the routine immunization schedule, such as 
in the US, Rotarix is administered together 
with other childhood vaccines, including 
d iphther ia - te tanus-ace l lu lar  per tuss i s 
(DTaP), inactivated poliovirus, hepatitis B, 
Haemophilus influenzae type B conjugate 
vaccine, and heptavalent pneumococcal 
conjugate vaccine.43 Thus, Rotarix may 
be conveniently administered at the time 
of the first and the second visits of DTaP 
immunization which, in the US, are scheduled 
to be given to infants at 2 and 4 months 
of age. Unfortunately, in Japan, the DTaP 
immunization does not start until the infant 
is 3 months of age. However, Rotarix can also 
be administered at 2 months of age together 
with Haemophilus influenzae type b conjugate 
vaccine or heptavalent pneumococcal 
conjugate vaccine. It may appear strange, 
however, to find in the package insert that 
such concomitant administration is allowed 
only when the immunization practitioner 
judges it necessary.35 
With regard to the oral polio vaccine, the 
expert group of ESPID/ESPGHAN discouraged 
co-administration with Rotarix in its guidelines45 
due to the insufficient clinical efficacy and safety 
data available to support it. However, there are 
data available that failed to detect any difference 
in efficacies46 or rotavirus Ig (immunoglobulin) 
A seroconversion rates47,48 between those who 
were co-administered Rotarix with oral polio 
vaccine and those who were not. Another issue 
specific to Japan may be the arrangement of 

























Figure 2. Age distribution of patients with naturally-
occurring intussusception in a sentinel hospital in northern 
Japan. Note that there was no case of intussusception 
during the first 3 months of life (0-2 months of age). 
Adapted from the figure published in Nakagomi T, 
Takahashi Y, Arisawa K, Nakagomi O. A high incidence 
of intussusception in Japan as studied in a sentinel hospital 
over a 25-year period (1978-2002). Epidemiol Infect. 
2006;134:57-61.40
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tuberculosis vaccine) immunization, which is 
administered between 3-6 months of age.
Contraindications
Contraindications include uncorrected 
congenital malformation of the gastrointestinal 
tract, such as Meckel’s diverticulum, because 
such malformation would predispose the 
infant to intussusception.35 The Centers for 
Disease Control and Prevention (CDC) in the 
US has recently updated the contraindications 
for rotavirus vaccines (Rotarix and RotaTeq) 
to include a history of intussusception.49 It 
has been reported that patients with severe 
combined immunodeficiency never eliminate 
the vaccine strains.50 Therefore, current 
contraindications are: (a) infants with a history 
of severe allergic reaction after a previous dose; 
(b) infants diagnosed with severe combined 
immunodeficiency; and (c) infants with a 
history of intussusception. 
THE RESULTS OF CLINICAL TRIAL 
OF ROTARIX IN JAPAN
Prior to filing an application for licensure 
in Japan, a phase 3, randomized (vaccine: 
placebo = 2:1 ratio), double-blind, placebo-
controlled clinical trial was conducted to 
evaluate the efficacy, reactogenicity, safety, 
and immunogenicity of Rotarix in Japanese 
infants when it was administered as two doses 
at 2 and 3 months of age.51 More specifically, 
765 infants aged 6-14 weeks were enrolled, of 
whom 750 were estimated to be administered the 
first dose (either the vaccine or the placebo) before 
12 weeks of age. Efficacy against any severe 
rotavirus gastroenteritis leading to medical 
intervention, caused by circulating wild-
type rotavirus, from 2 weeks after the second 
dose until 2 years of age was 79.3% (95% CI: 
60.5-89.8%) and 91.6% (95% CI: 62.4-99.1%), 
respectively. Seroconversion at the time of 1 
month after the second dose was 85% (95% 
CI: 68.9-95%) in the Rotarix group, whereas 
only one in 20 infants (5%) in the placebo 
group seroconverted (due to wild-type rotavirus 
infection).
TWO KEY ISSUES RELATING TO 
THE ROTARIX INTRODUCTION IN 
JAPAN
Lastly, the authors will conclude this review by 
addressing the two important issues. These issues 
fall on the specific area of rotavirus research 
where the authors believe that they have expert 
views; whether Rotarix is effective in preventing 
severe diarrhea caused by fully heterotypic 
G2P[4] rotavirus strains and whether Rotarix is 
safe with respect to intussusception.
The first issue is about a persisting concern 
derived from the fact that Rotarix is a vaccine 
containing only a single human G1P[8] 
strain, RIX4414. The guiding principle for 
the development of a single-strain human 
rotavirus vaccine was that the induction of 
protective immunity does not entirely depend 
on neutralizing antibodies specific to either G 
or P serotype, but more on factors that mediate 
heterotypic immunity.52-55 In a large clinical 
trial in Latin America, and later in Europe, 
Rotarix was shown to be effective in preventing 
severe rotavirus diarrhea caused by partially 
heterotypic G3P[8], G4P[8], and G9P[8] strains, 
as well as fully-homotypic G1P[8] strains.56,57
Since fully-heterotypic G2P[4] strains were 
infrequent during these clinical trials, protective 
efficacy appeared less convincing, with wide 
95% CIs. Soon after the introduction of Rotarix 
into the universal immunization schedule in 
Brazil, Gurgel et al.58 and Nakagomi et al.59
noticed a high predominance of G2P[4] strains, 
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although there was also a simultaneous marked 
decrease in the detection rate of rotavirus.59
While these studies suggested a shift in the 
predominantly circulating strains to G2P[4] in 
highly vaccinated regions, it remained unclear 
whether such phenomena resulted from Rotarix 
use or were a simple reflection of natural 
variation.60-62 Thus, the key issue here is whether 
Rotarix would be effective in preventing severe 
rotavirus diarrhea caused by fully-heterotypic 
G2P[4] strains. Three case-control studies to 
quantitatively measure the effectiveness of 
Rotarix against G2P[4] strains were carried out 
in different locations in Brazil.63-65 In the areas 
of Brazil where these studies were conducted 
the proportion of G2P[4] genotypes were high 
(82%-100%), and the effectiveness of Rotarix 
against severe acute diarrhea or hospitalization 
due to G2P[4] strains were 79% (95% CI: 74-82) 
in Aracaju,63 85% (95% CI: 54-95) in Recife,64
and 75% (95% CI: 57-86) in Belém.65 These 
data provide strong evidence for the protective 
efficacy of Rotarix even against rotaviruses 
fully heterotypic to the vaccine strain. This has 
important implications because Rotarix would 
also be expected to provide a reasonable level 
of protection against fully heterotypic strains 
other than G2P[4]; these include G12P[6], 
prevalent in Nepal,14 and G8P[6], prevalent in 
Malawi.16 However, a recent study that analyzed 
an outbreak of gastroenteritis hospitalizations 
caused by G2P[4] rotavirus in an impoverished 
region in Australia failed to provide evidence of 
effectiveness against G2P[4] rotavirus strains.66
Thus, the issue of protection against fully-
heterotypic G2P[4] strains still warrants closer 
attention, especially in poorer regions.
The second issue concerns the safety of 
Rotarix with respect to intussusception. This 
safety was established in a large-scale clinical 
trial involving more than 63,000 infants from 
11 countries in Latin America and Finland. 
This trial revealed no statistically significant 
increases in the risk of Rotarix causing 
intussusception when it was administered 
to infants aged between 6-12 weeks in 10 
Latin American countries (Figure 1), between 
6-13 weeks in Chile, and 6-14 weeks in 
Finland.7 The study was powered to detect 
as small a risk as approximately six cases 
per 10,000 vaccine recipients; it was, thus, 
concluded that Rotarix was not considered 
to cause intussuseption as frequently as 
Rotashield® (Wyeth-Lederle Vaccines, Radnor, 
PA, USA) did. However, two postlicensure 
studies conducted in Mexico and Brazil 
detected a small, yet statistically significant, 
relative risk of 5.3 (95% CI: 3.9-9.3), translating 
into an excess risk of intussuseption of one 
in 51,000 vaccinees in Mexico in the first 
week after the first dose; a relative risk of 2.6 
(95% CI: 1.3-5.2), in Brazil, translating into 
an excess risk of one in 68,000 vaccinees in 
the first week after the second dose.67 These 
risks were smaller than those that prelicensure 
clinical trials were powered to detect. Another 
study conducted in Australia, where either 
Rotarix or RotaTeq were introduced into the 
universal immunization program depending 
on the Australian state, detected a relative risk 
of 3.5 (95% CI: 0.7-10.1) in the first week after 
the first dose of Rotarix, and a relative risk of 
5.3 (95% CI: 1.1-15.4) in the first week after 
the first dose of RotaTeq.68 The implications 
from these studies are clear; firstly, the 
hypothesis that intussusception is unique to 
the Rotashield vaccine and that other rotavirus 
vaccines are inherently free from the risk of 
intussusception has clearly been questioned. 
Secondly, since RIX4414 was originally derived 
from a virulent human rotavirus, natural 
infection with wild-type rotavirus can also 
cause intussusceptions; a hypothesis that the 
authors have previously maintained.69,70
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Reviewing these emerging data and 
recognizing a very small, yet finite, level of 
risk associated with the Rotarix vaccination, 
the authors conclude that Rotarix is safe 
to administer to infants at the globally-
recommended age period, such as between 
6-12 weeks of age, when naturally occurring 
intussusception is rare (Figures 1 and 2). On 
the other hand, the authors see no reason to 
be bold enough to recommend the Rotarix 
immunization beyond 13-15 weeks of age, as 
is allowed according to the package insert of 
Rotarix in Japan35 and promotional pamphlets.37
The benefits that will be gained by expanding 
the immunization period for the first dose to 
20 weeks of age very unlikely outweighs the risk 
of an increased number of intussusception cases, 
whose causal relationship with Rotarix will 
never be ruled out at the individual case level. 
If one were to suppose that the attributable risk 
is 5%, there would be no way to tell which one 
of 20 patients (5%) with intussusception that 
occurred in the first week after the first dose was 
due to the vaccine. A greater number of such 
temporally associated cases of intussusception 
would be expected in Japan than in countries 
such as Australia and the US. This is due to 
the greater incidence of intussusception in 
the first year of life in Japan (185 per 100,000 
people/year [95% CI: 133-250])40 than in the US 
(30-50 per 100,000 people/year)71 or Australia 
(71 per 100,000 people/year [95% CI: 52-97]).72
CONCLUSION
A live-attenuated, orally-administered, 
monovalent rotavirus vaccine, Rotarix, has 
been launched on the Japanese market. Rotarix 
has, thus far, shown a remarkable track record 
in the reduction of morbidity and mortality 
primarily in Latin American countries, purging 
itself of the skepticism regarding its effectiveness 
against serologically unrelated G2P[4] strains. 
While recent postlicensure surveillance detected 
a small, yet finite, risk of Rotarix causing 
intussusception, the authors conclude that 
Rotarix is safe to administer to infants between 
6-12 weeks of age for the first dose and by 
24 weeks of age for the second dose. However, 
the authors strongly discourage the delayed 
administration of the first dose between 
13-20 weeks of age, which is allowed without any 
warning. Given the high incidence of naturally 
occurring intussusception in Japan, this should 
prevent pediatricians and parents from having 
ill-perceptions of Rotarix being associated with 
an increased number of temporally associated 
intussusception, and fully appreciate the benefit 
of the rotavirus vaccine. 
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